Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.

医学 成纤维细胞生长因子受体 肿瘤科 内科学 成纤维细胞生长因子 受体
作者
Shubham Pant,Joon Oh Park,Wu‐Chou Su,Martin Schüler,Yohann Loriot,Gopa Iyer,Toshihiko Doi,Shukui Qin,Josep Tabernero,Hans Prenen,Gunnar Folprecht,Helen Winter,Graziela Zibetti Dal Molin,Hussein Sweiti,Saltanat Najmi,Constance Hammond,Huimin Liao,Shibu Thomas,Spyros Triantos,Yin‐Hsun Feng
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 4121-4121
标识
DOI:10.1200/jco.2024.42.16_suppl.4121
摘要

4121 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for the treatment of adult pts with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations whose disease has progressed on or after ≥1 line of prior systemic therapy. Primary analysis of the RAGNAR study demonstrated tumor agnostic efficacy in patients with solid tumors harboring susceptible FGFR mutations or fusions (1). Results from the LUC2001 study in patients with cholangiocarcinoma were previously presented (2). Here we report on the pooled analysis of patients with cholangiocarcinoma treated in the RAGNAR and LUC2001 studies. Methods: RAGNAR (NCT04083976) and LUC2001 (NCT02699606) enrolled patients with advanced solid tumors after ≥1 prior lines of therapy. RAGNAR patients had exhausted standard of care therapies; LUC2001 enrolled patients only in China, Taiwan, and South Korea. Patients received erdafitinib (8 mg daily, optional up-titration) until disease progression or toxicity. Patients with cholangiocarcinoma and predefined FGFR alterations were pooled into an analysis of efficacy (objective response rate by Independent Review Committee [IRC], duration of response, progression free survival, overall survival) and safety. Results: At data cutoff, 78 patients had received erdafitinib (RAGNAR: 66; LUC2001: 12). Median efficacy follow-up was 15 months. Median (range) age was 56 years (24;77); 60% female, 47% White, 39% Asian. Patients had a median of 2 prior lines of therapy; 92% patients had visceral metastases, and 17% of patients responded to prior therapy. 94% of patients had FGFR2 alterations, and 91% of patients had fusions. Objective response rate by IRC was 55%. Responses were observed in patients with both, fusions or mutations. Median time to onset of response was 1.7 month; median duration of response, progression free survival, and overall survival were 6.9 (95% CI: 4.37, 8.61), 8.5 (95% CI: 6.83, 9.72), and 18.1 (95% CI: 13.40, 24.28) months, respectively. Most common treatment-emergent adverse events (TEAEs) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), palmar-plantar erythrodysesthesia (51%); 42% of patients had serious TEAEs and 12% discontinued treatment due to an AE. No treatment-related deaths were observed. Conclusions: Data from pooled analysis of the RAGNAR and LUC2001 studies confirm robust efficacy of erdafitinib in a diverse population of patients with advanced or metastatic cholangiocarcinoma and prespecified FGFRfusions or mutations. Safety data were consistent with the erdafitinib safety profile. 1. Pant 2023. 2. Feng 2022. Clinical trial information: NCT04083976 and NCT02699606 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rondab应助机灵枕头采纳,获得10
4秒前
佳无夜完成签到,获得积分10
9秒前
摆哥完成签到,获得积分10
13秒前
66完成签到,获得积分10
18秒前
zlqq完成签到 ,获得积分10
18秒前
Hardskills发布了新的文献求助10
21秒前
22秒前
之_ZH完成签到 ,获得积分10
30秒前
gds2021完成签到 ,获得积分10
32秒前
你好呀嘻嘻完成签到 ,获得积分10
32秒前
梅特卡夫完成签到,获得积分10
34秒前
熊雅完成签到,获得积分10
35秒前
37秒前
睡到自然醒完成签到 ,获得积分10
38秒前
cis2014完成签到,获得积分10
40秒前
独特的大有完成签到 ,获得积分10
40秒前
量子星尘发布了新的文献求助10
41秒前
43秒前
xingyi完成签到,获得积分10
45秒前
46秒前
舒心的秋荷完成签到 ,获得积分10
49秒前
zz123发布了新的文献求助10
50秒前
liaomr完成签到 ,获得积分10
50秒前
粗犷的灵松完成签到,获得积分10
51秒前
吃小孩的妖怪完成签到 ,获得积分10
51秒前
ncuwzq完成签到,获得积分10
53秒前
yshj完成签到 ,获得积分10
54秒前
56秒前
净禅完成签到 ,获得积分10
58秒前
1分钟前
迷人的寒风完成签到,获得积分10
1分钟前
1分钟前
water应助科研通管家采纳,获得10
1分钟前
Lucas应助HHHAN采纳,获得10
1分钟前
无情修杰完成签到 ,获得积分10
1分钟前
小柒完成签到 ,获得积分10
1分钟前
聪慧芷巧发布了新的文献求助10
1分钟前
1分钟前
1分钟前
蓝意完成签到,获得积分0
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022